Abnormal metabolism in the progression of nonalcoholic fatty liver disease to hepatocellular carcinoma: Mechanistic insights to chemoprevention

Abstract

Nonalcoholic fatty liver disease (NAFLD) is on the rise and becoming a major contributor to the development of hepatocellular carcinoma (HCC). Reasons for this include the rise in obesity and metabolic syndrome in contrast to the marked advances in prevention and treatment strategies of viral HCC. These shifts are expected to rapidly propel this trend even further in the coming dec-ades, with NAFLD on course to become the leading etiology of end-stage liver disease and HCC. No Food and Drug Administration (FDA)-approved medications are currently available for the treatment of NAFLD, and advances are desperately needed. Numerous medications with varying mechanisms of action targeting liver steatosis and fibrosis are being investigated including peroxi-some proliferator-activated receptor (PPAR) agonists and farnesoid X receptor (FXR) agonists. Ad-ditionally, drugs targeting components of metabolic syndrome, such as antihyperglycemics, have been found to affect NAFLD progression and are now being considered in the treatment of these patients. As NAFLD drug discovery continues, special attention should be given to their relationship to HCC. Several mechanisms in the pathogenesis of NAFLD have been implicated in hepato-carcinogenesis, and therapies aimed at NAFLD may additionally harbor independent antitumor-igenic potential. This approach may provide novel prevention and treatment strategies.